• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Snap Inc.

    5/22/25 8:00:10 AM ET
    $SNAP
    Computer Software: Programming Data Processing
    Technology
    Get the next $SNAP alert in real time by email
    SD 1 d64010dsd.htm SD SD
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    Form SD

     

     

    SPECIALIZED DISCLOSURE REPORT

     

     

    SNAP INC.

    (Exact name of the registrant as specified in its charter)

     

     

     

    Delaware   001-38017   45-5452795

    (State or other jurisdiction

    of incorporation or organization)

      (Commission File Number)  

    I.R.S. Employer

    Identification No.

     

    3000 31st Street, Santa Monica, California   90405
    (Address of principal executive offices)   (Zip code)

    Michael O’Sullivan

    General Counsel

    (310) 399-3339

    (Name and telephone number, including area code,

    of the person to contact in connection with this report.)

     

     

    Check the appropriate box below to indicate the rule pursuant to which this Form is being submitted, and provide the period to which the information in this Form applies:

     

    ☒

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

     

    ☐

    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended ______.

     

     
     


    Section 1 – Conflict Minerals Disclosure

     

    Item 1.01

    Conflict Minerals Disclosure and Report

    In accordance with Rule 13p-1 under the Securities Exchange Act of 1934, as amended, and Form SD, we are filing as an exhibit to this Form SD a Conflict Minerals Report for the year ended December 31, 2024. A copy of our Conflict Minerals Report is provided as Exhibit 1.01 to this Form SD and is available on our website at www.snap.com under the heading “Other Terms & Policies.” Information contained on or accessed through our website is not incorporated by reference into this Form SD or our Conflict Minerals Report and should not be considered part of this Form SD or the Conflict Minerals Report.

    Information concerning conflict minerals from recycled or scrap sources identified by our suppliers as potentially being contained within our in-scope products is included in the Conflict Minerals Report and is incorporated in this Form SD by reference.

     

    Item 1.02

    Exhibit

    Our Conflict Minerals Report for the year ended December 31, 2024, as contemplated by Item 1.02, is filed as Exhibit 1.01 to this Form SD.

    Section 2 – Resource Extraction Issuer Disclosure

     

    Item 2.01

    Resource Extraction Issuer Disclosure and Report

    Not applicable.

    Section 3 – Exhibits

     

    Item 3.01

    Exhibit

    Exhibit 1.01 – Conflict Minerals Report for the year ended December 31, 2024.


    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

    SNAP INC.

     

    /s/ Michael O’Sullivan

      May 22, 2025
    By:   Michael O’Sullivan   Date
    Title:   General Counsel  
    Get the next $SNAP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNAP

    DatePrice TargetRatingAnalyst
    2/11/2025Buy → Neutral
    Guggenheim
    2/5/2025Overweight
    Barclays
    2/5/2025$15.00 → $11.00Overweight → Equal Weight
    Wells Fargo
    10/23/2024$17.00Mkt Perform → Mkt Outperform
    JMP Securities
    9/20/2024$11.00Neutral
    B. Riley Securities
    9/5/2024$8.00Neutral
    Cantor Fitzgerald
    8/2/2024Buy → Hold
    HSBC Securities
    7/23/2024$12.00 → $16.00Underweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $SNAP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • June 7, 2024 - FDA Roundup: June 7, 2024

      For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

      6/7/24 3:46:22 PM ET
      $GERN
      $SRAX
      $SNAP
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Advertising
      Consumer Discretionary
    • March 22, 2024 - FDA Roundup: March 22, 2024

      For Immediate Release: March 22, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued an emergency use authorization for Pemgarda (pemivibart) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents (12 years of age and older weighing at least 40 kilograms [about 88 pounds]).  Pemgarda is

      3/22/24 5:02:42 PM ET
      $SNAP
      $SRAX
      Computer Software: Programming Data Processing
      Technology
      Advertising
      Consumer Discretionary
    • November 9, 2023 - FDA Approves First Treatment for Patients with Rare Inherited Blood Clotting Disorder

      For Immediate Release: November 09, 2023 Today, the U.S. Food and Drug Administration approved Adzynma, the first recombinant (genetically engineered) protein product indicated for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), a rare and life-threatening blood clotting disorder. “The FDA remains

      11/9/23 2:30:20 PM ET
      $SRAX
      $SNAP
      Advertising
      Consumer Discretionary
      Computer Software: Programming Data Processing
      Technology